Entinostat/Erlotinib Hydrochloride

恩替诺特/盐酸厄洛替尼

Report date: 2026/04/29 17:37:58

Base Information

Drug NameEntinostat/Erlotinib Hydrochloride
Drug Alias Name盐酸厄洛替尼/恩替诺特entinostat/erlotinibErlotinib Hydrochloride/Entinostat
ClassificationSmall molecules
Mechanisms of ActionHistone deacetylase 2 inhibitorsEpidermal growth factor receptor erbB1 antagonistsHistone deacetylase 3 inhibitors +[4] 
TargetsHistone deacetylase 2Histone deacetylase 1Histone deacetylase 3 +[4] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes EntinostatErlotinib Hydrochloride
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesColorado State University FoundationSyndax Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSyndax Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A